COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.

Rakesh Gopinathan NairFaisal M MerchantDhanunjaya R LakkireddySusan P EtheridgeSuzy FeigofskyJanet K HanRajesh KabraAndrea NataleStacy PoeSandeep A SahaAndrea M Russo

Published in: Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing (2020)

In this global survey of > 1100 EP professionals regarding hospitalized COVID-19 patients, a variety of arrhythmic manifestations were observed, ranging from benign to potentially life-threatening. Observed adverse events related to use of HCQ + AZM included prolonged QTc requiring drug discontinuation as well as Torsade de Pointes. Large prospective studies to better define arrhythmic manifestations as well as the safety of treatment strategies in COVID-19 patients are warranted.

Keyphrases

sars cov
drug induced
coronavirus disease
respiratory syndrome coronavirus
left ventricular
cross sectional
congenital heart disease
adverse drug